"Sobi has been through a significant transformation in the past few years and we are now well positioned for the next phase," says
Highlights of the Capital Markets Day
Capture the value of the pipeline: By delivering on our late-stage pipeline, we will further enhance patient access to innovative medicine and the growth profile of the company. Sobi today has 12 late-stage programmes with the potential to meet significant unmet medical need and position Sobi for long-term growth.
Lead in Haematology and grow Immunology: Sobi's core products within Haematology and Immunology are expected to continue to deliver strong growth driven by new indications, new markets and further patient gains over the planning horizon until 2025.
Go global: Sobi will continue the ongoing internationalisation of its operations. Recently added products with global rights open up new opportunities outside of
Revenue
The ambition is to reach revenue of
Increased investments in R&D and commercialisation:
The recent additions to the late-stage pipeline will drive investments in R&D mid-term. The previous level of R&D costs at around 10 per cent of revenue is expected to increase to 13-15 per cent during 2021-2022.
Launches and internationalisation of operations will require further investments in infrastructure and increase SG&A spend over revenue short term.
The EBITA margin is expected to accelerate from 2023.
About Sobi[TM]
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenue amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.
This information is information that
Contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/realising-opportunities-for-future-growth-and-financial-update--sobi-capital-markets-day-2020,c3252081
https://mb.cision.com/Main/14266/3252081/1346484.pdf
(c) 2020 Cision. All rights reserved., source